Topics

BIA Separations selected for manufacturing process development support for gene therapy pipeline.

13:05 EDT 22 Jul 2019 | Zyme Communications

BIA Seperations

  • BIA Separations will provide expertise in next generation biomolecule purification processes and long-term supply of CIMmultus™ monolithic columns
  • Initial focus on the manufacture of Zolgensma®, a gene therapy for pediatric patients with spinal muscular atrophy (SMA) less than the age of 2

Ajdovšcina, Slovenia, 22nd July 2019: BIA Separations, a leading biochromatography development and manufacturing company, today announced it is collaborating with AveXis, a Novartis company, to enhance the commercial purification process for its gene therapy pipeline, beginning with Zolgensma® (onasemnogene abeparvovec-xioi), the first U.S. Food and Drug Administration-approved gene therapy indicated for the treatment of pediatric patients with spinal muscular atrophy (SMA) who are less than two years of age.

Zolgensma is a one-time infusion that provides a functional copy of the human SMN gene to halt disease progression through sustained SMN protein expression.

BIA was selected as a result of its expertise in viral and DNA purification, particularly adeno-associated virus (AAV), and chromatographic technology for the purification and analysis of biomolecules.

Aleš Štrancar, CEO of BIA Separations commented: “We are proud to have been selected to support AveXis’ gene therapy pipeline. We look forward to seeing how Zolgensma helps the SMA community and the whole BIA team is honored to be a part of this important work.”

Andy Stober, Senior Vice President of Technical Operations for AveXis added: “We are especially grateful that BIA Separations shared, and operated, with the same sense of urgency we did to help bring gene therapy to the SMA community. BIA’s experience with AAV purification and its chromatographic technology were important contributions and we look forward to our continued work together.”

ENDS

Notes to Editors

For high resolution images please email sarah.jeffery@zymecommunications.com

Media contact

Sarah Jeffery
Zyme Communications
E: sarah.jeffery@zymecommunications.com
T: +44 (0)7771 730 919

At BIA Separations
Jana Krapež Trošt
Head of Marketing
E: marketing@monoliths.com
T: +386 (0)59 699 505

About BIA Separations www.biaseparations.com

BIA Separations is the leading developer and manufacturer of CIM® (Convective Interaction Media) monolithic chromatographic columns for production, purification, and analytics of large biomolecules. The company has research and production facilities in Slovenia, with sales offices and distributors throughout the world. BIA Separations’ mission is to develop and produce CIM® monolithic columns of highest quality and provide superior research and method development services for purification and analytics of biomolecules. In addition, the company aims to provide unique in-process control tools to better understand and control the bioprocesses.

Zolgensma® is a registered trademark of AveXis, Inc. a Novartis company.

CIMmultus™ and CIM® are registered trademarks of BIA Separations.

NEXT ARTICLE

More From BioPortfolio on "BIA Separations selected for manufacturing process development support for gene therapy pipeline."

Quick Search

Relevant Topics

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...